Sagimet Biosciences Inc
Company Profile
Business description
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Contact
155 Bovet Road
Suite 303
San MateoCA94402
USAT: +1 650 561-8600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,713.10 | 86.30 | -0.98% |
| CAC 40 | 7,981.76 | 5.73 | -0.07% |
| DAX 40 | 24,400.65 | 92.73 | 0.38% |
| Dow JONES (US) | 49,363.88 | 322.24 | -0.65% |
| FTSE 100 | 10,330.55 | 6.80 | 0.07% |
| HKSE | 25,655.44 | 142.41 | -0.55% |
| NASDAQ | 25,870.71 | 220.02 | -0.84% |
| Nikkei 225 | 59,549.16 | 1,001.43 | -1.65% |
| NZX 50 Index | 12,763.67 | 210.65 | -1.62% |
| S&P 500 | 7,353.61 | 49.44 | -0.67% |
| S&P/ASX 200 | 8,491.50 | 81.60 | -0.95% |
| SSE Composite Index | 4,150.98 | 18.56 | -0.45% |